SCHEDULE 4

Regulation 3

PART I CONTROLLED DRUGS SUBJECT TO THE REQUIREMENTS OF REGULATIONS 22, 23, 26 AND 27

1

The following substances and products, namely—

  • Alprazolam

  • Aminorex

  • Bromazepam

  • Brotizolam

  • Camazepam

  • Chlordiazepoxide

  • F51–(3–chlorophenyl)piperazine

  • F51–(3–chlorophenyl)–4–(3–chloropropyl)piperazine

  • Clobazam

  • Clonazepam

  • Clorazepic acid

  • Clotiazepam

  • Cloxazolam

  • Delorazepam

  • Diazepam

  • Estazolam

  • Ethyl loflazepate

  • Fencamfamin

  • Fenproporex

  • Fludiazepam

  • Flurazepam

  • Halazepam

  • Haloxazolam

  • F21...

  • F22...

  • Ketazolam

  • Loprazolam

  • Lorazepam

  • Lormetazepam

  • Medazepam

  • Mefenorex

  • Mesocarb

  • F4...

  • Nimetazepam

  • Nitrazepam

  • Nordazepam

  • Oxazepam

  • Oxazolam

  • Pemoline

  • Pinazepam

  • Prazepam

  • Pyrovalerone

  • F24Remimazolam

  • Tetrazepam

  • Triazolam

  • N-Ethylamphetamine

  • F19Zaleplon

  • F1Zolpidem

  • F20Zopiclone

2

Any stereoisomeric form of a substance specified in paragraph 1.

3

Any salt of a substance specified in paragraph 1 or 2.

4

Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 3, not being a preparation specified in Schedule 5.

F185

A liquid formulation—

a

containing a botanical extract of cannabis—

i

with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and

ii

where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,

b

which is dispensed through a metered dose pump as a mucosal mouth spray, and

c

which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010

PART IIF17Controlled Drugs Excepted From the Prohibition on Possession; Excluded from the Application of Offences Arising from the Prohibition on Importation and Exportation when Carried Out in Person for Administration to That Person; and Subject to the Requirements of Regulations 22, 23, 26 and 27

Annotations:
Amendments (Textual)

1

The following substances, namely—

  • F65α–Androstane–3,17–diol

  • F6Androst-4-ene-3,17-diol

  • F61–Androstenediol

  • F61–Androstenedione

  • F24-Androstene-3, 17-dione

  • F75–Androstenedione

  • F25-Androstene-3, 17 diol

  • Atamestane

  • Bolandiol

  • Bolasterone

  • Bolazine

  • Boldenone

  • F10Boldione

  • Bolenol

  • Bolmantalate

  • Calusterone

  • 4-Chloromethandienone

  • Clostebol

  • F8Danazol

  • F8Desoxymethyltestosterone

  • F23Dienedione (estra-4, 9-diene-3,17-dione)

  • Drostanolone

  • Enestebol

  • Epitiostanol

  • Ethyloestrenol

  • Fluoxymesterone

  • Formebolone

  • Furazabol

  • F9Gestrinone

  • F93–Hydroxy–5α–androstan–17–one

  • Mebolazine

  • Mepitiostane

  • Mesabolone

  • Mestanolone

  • Mesterolone

  • Methandienone

  • Methandriol

  • Methenolone

  • Methyltestosterone

  • Metribolone

  • Mibolerone

  • Nandrolone

  • F1119–Norandrostenedione

  • F319-Nor-4-Androstene-3, 17-dione

  • F319-Nor-5-Androstene-3, 17 diol

  • F1219–Norandrosterone

  • Norboletone

  • Norclostebol

  • Norethandrolone

  • F1319–Noretiocholanolone

  • Ovandrotone

  • Oxabolone

  • Oxandrolone

  • Oxymesterone

  • Oxymetholone

  • Prasterone

  • Propetandrol

  • F14Prostanozol

  • Quinbolone

  • Roxibolone

  • Silandrone

  • Stanolone

  • Stanozolol

  • Stenbolone

  • Testosterone

  • F15Tetrahydrogestrinone

  • Thiomesterone

  • Trenbolone

2

Any compound (not being Trilostane or a compound for the time being specified in paragraph 1 of this Part of this Schedule) structurally derived from 17-hydroxyandrostan-3-one or from 17-hydroxyestran-3-one by modification in any of the following ways, that is to say -

a

by further substitution at position 17 by a methyl or ethyl group;

b

by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

c

by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;

d

by fusion of ring A with a heterocyclic system.

3

Any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in paragraph 1 or described in paragraph 2 of this Part of this Schedule.

4

The following substances, namely—

  • Chorionic Gonadotrophin (HCG)

  • Clenbuterol

  • Non-human chorionic gonadotrophin

  • Somatotropin

  • Somatrem

  • Somatropin

  • F16Zeranol

  • F16Zilpaterol

5

Any stereoisomeric form of a substance specified or described in any of paragraphs 1 to 4 of this Part of this Schedule.

6

Any salt of a substance specified or described in any of paragraphs 1 to 5 of this Part of this Schedule.

7

Any preparation or other product containing a substance or product specified or described in any of paragraphs 1 to 6 of this Part of this Schedule, not being a preparation specified in Schedule 5.